Loading…
Employees: 1,522
Size Shin Nippon Biomedical Laboratories (2395.T) is a Japan Industrials company (Miscellaneous Commercial Services) with a market value of $360M, the 1247th largest of 1,379 Japan companies the cockpit tracks. Shares closed at ¥1,362 on 6 Nov 2026.
Performance Over six months the shares fell 4.9%, against -22.1% for the median peer and +1.8% for the Japan market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 1.7% over the last twelve months (peer median +5.5%); the operating margin is 10.4% (peer median 6.5%).
Valuation It trades at 14.5× forward earnings against a peer median of 17.8× (3rd cheapest of 13).
Price implies For today's price to make sense, revenue must grow about 7% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is -10 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.3 points below its cost of capital (5.0% WACC).
Next results Next results expected around 10 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥33.9B | ¥32.5B | ¥32.4B | ¥26.5B | ¥25.1B |
| Revenue growth | — | 0% | +23% | +5% | — |
| Gross profit | ¥17.2B | ¥15.8B | ¥16.6B | ¥14.0B | ¥12.8B |
| EBITDA | ¥6.99B | ¥6.09B | ¥5.60B | ¥6.03B | ¥6.85B |
| Net income | ¥5.37B | ¥4.57B | ¥4.92B | ¥5.53B | ¥6.06B |
| Free cash flow | n/a | ¥3.15B | -¥3.82B | -¥6.48B | -¥836M |
| Capital expenditure | n/a | ¥5.34B | ¥10.9B | ¥8.61B | ¥4.96B |
| Total debt | ¥37.6B | ¥41.4B | ¥34.6B | ¥26.3B | ¥18.9B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 2395.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -6.1% | -1.4% | 10th lowest of 21 |
| 6-month return | -4.9% | -22.1% | 7th highest of 21 |
| Distance from 52-week high | -32.1% | -43.7% | 7th highest of 21 |
| Revenue growth (TTM) | +1.7% | +5.5% | 7th lowest of 21 |
| Operating margin | 10.4% | 6.5% | 7th highest of 20 |
| Forward P/E | 14.5× | 17.8× | 3rd cheapest of 13 |
| Growth the price implies (Req g, 7 yrs) | 6.9% | 10.9% | 4th least demanding of 11 |
| Growth delivered (Del g) | +16.6% | +3.2% | 4th highest of 11 |
| Hurdle (Req g minus delivered) | -9.6 pp | +3.2 pp | 5th least demanding of 11 |
| ROIC minus cost of capital | -1.3 pp | -4.6 pp | 6th highest of 19 |
| EV / EBITDA | 11.5× | 7.9× | 5th most expensive of 10 |
| Net debt / EBITDA | 3.3× | -1.3× | 3rd most indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shin Nippon Biomedical Laboratories 2395.T | Japan | $360M | -5% | +2% | 10% | 14.5× | 6.9% | +16.6% |
| ECOPRO HN 383310.KS | South Korea | $360M | -27% | -27% | 9% | 17.5× | n/a | n/a |
| Roma Green Finance ROMA | United States | $360M | -1% | -22% | -315% | n/a | n/a | n/a |
| Optima Health OPT.L | United Kingdom | $361M | +29% | +15% | 3% | 18.8× | 29.6% | +1.5% |
| Globe-Ing 277A.T | Japan | $361M | -16% | +31% | 34% | 16.8× | -3.6% | +31.2% |
| Jiayuan Science And Technology 301117.SZ | China | $358M | -57% | -41% | -67% | 26.0× | n/a | n/a |
| Qingdao Greensum Ecology 300948.SZ | China | $357M | -30% | +83% | -30% | n/a | n/a | n/a |
| Hargreaves Services HSP.L | United Kingdom | $363M | +8% | +33% | 4% | 18.0× | 9.2% | +11.4% |
| Tianjin LVYIN Landscape & Ecology Construction 002887.SZ | China | $354M | -41% | -8% | 12% | 17.1× | 11.3% | -13.0% |
| Ningbo Color Master Batch 301019.SZ | China | $354M | -31% | +14% | 21% | n/a | 10.4% | +1.8% |
| Avacta AVCT.L | United Kingdom | $352M | -24% | -100% | -27,388% | n/a | n/a | n/a |
| Omni Bridgeway OBL.AX | Australia | $367M | +8% | +75% | -15% | 9.7× | n/a | n/a |
| RattanIndia Enterprises RTNINDIA.NS | India | $368M | -37% | +2% | 1% | n/a | n/a | n/a |
| Corporate Travel Management CTD.AX | Australia | $350M | -69% | +7% | 6% | 19.5× | 12.0% | +30.6% |
| Axactor ACR.OL | Norway | $370M | -20% | -146% | n/a | n/a | n/a | n/a |
| Zhejiang Xidamen New Material 605155.SS | China | $349M | -23% | +4% | 12% | 15.7× | -0.9% | +20.0% |
| Shenzhen Ridge Technology 300977.SZ | China | $349M | -27% | +13% | -2% | 31.9× | 33.2% | -4.0% |
| Insource 6200.T | Japan | $347M | -1% | +7% | 40% | 11.1× | n/a | n/a |
| Takara & 7921.T | Japan | $346M | +23% | +4% | 15% | n/a | -11.6% | +4.7% |
| Beijing Kaiwen Education Technology 002659.SZ | China | $376M | -22% | +7% | 8% | 119.7× | 15.8% | +1.5% |
| Pico Far East 0752.HK | Hong Kong | $342M | -14% | +3% | 6% | n/a | n/a | n/a |